FDA Endorses Zepbound for Sleep Apnea Linked to Obesity

FDA Endorses Zepbound for Sleep Apnea Linked to Obesity

The U.S. Food and Drug Administration has sanctioned the prescription of Zepbound for adults struggling with obesity and severe obstructive sleep apnea.

Zepbound is the pioneering medication approved specifically for managing obstructive sleep apnea.

On Friday, the FDA granted authorization for Zepbound, developed by Eli Lilly & Co., targeting adults suffering from obesity and moderate to severe obstructive sleep apnea. The agency suggests pairing the drug with a low-calorie diet and increased physical activity.

Obstructive sleep apnea, often exacerbated by excess weight, occurs when blockages in the upper airway disrupt breathing during sleep.

Research indicated by the FDA demonstrates that weight reduction facilitated by Zepbound alleviates sleep apnea symptoms in certain patients.

Two clinical trials involving obese adults and serious sleep apnea revealed that over 52 weeks, participants taking Zepbound reported a significant reduction in episodes of shallow breathing or apnea during sleep, as opposed to those on a placebo.

This was observed in participants regardless of CPAP machine use.

Dr. Sally Seymour, Director of the FDA's Division of Pulmonology, stated, "This marks a critical advancement for those battling obstructive sleep apnea."

The endorsement aligns with existing medical advice emphasizing the importance of weight management in mitigating sleep apnea.

This arrival dovetails with ongoing debates over the expanding roles of weight loss medications in tackling issues beyond obesity, like sleep apnea, and possibly addiction.

Though GLP-1 agonists were initially formulated two decades back, the exploration of their broader applications is in its infancy.

Known scientifically as tirzepatide, Zepbound was already cleared by the FDA in November 2023 for obesity treatment, positioning it as a challenger to Novo Nordisk's highly successful Wegovy.

Previously, in March, the FDA also authorized the use of Wegovy for decreasing the risk of cardiovascular incidents like strokes and heart attacks in at-risk, overweight individuals.

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Posts